Chabner Colloquium:
Answering the Big Questions in Cancer Research
2018 STO Annual Meeting

Featuring expert faculty providing updates on the most promising targets for development of new cancer treatments.

November 5, 2018
The Liberty Hotel
215 Charles Street
Boston, Massachusetts
# Chabner Colloquium:
Answering the Big Questions in Cancer Research

**Monday, November 5, 2018**

### Session 1: Novel Targets and Biomarkers
**Moderator:** David Spriggs, MD, MGH Cancer Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:45AM*</td>
<td>Beyond PARP1: Ribosylation as a Target for Cancer Therapy</td>
<td>Victoria Richon, PhD</td>
<td>Ribon Therapeutics</td>
</tr>
<tr>
<td>8:30AM</td>
<td>Melanoma: Clues to Improved Therapeutic Efficacy from Disease Pathogenesis</td>
<td>David E. Fisher, MD, PhD</td>
<td>MGH</td>
</tr>
<tr>
<td>9:15AM</td>
<td>Targeting Cell Death Pathways with Precision Using Functional Assays</td>
<td>Anthony Letai, MD, PhD</td>
<td>Dana-Farber Cancer Institute</td>
</tr>
<tr>
<td>10:00AM</td>
<td>Break/Exhibits</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Session 2: Enhanced Technology for Early Detection of Cancer
**Moderator:** David Spriggs, MD, MGH Cancer Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:20AM</td>
<td>Microfluidics for the Characterization of Tumor-specific Extracellular Vesicles</td>
<td>Shannon Stott, PhD</td>
<td>MGH</td>
</tr>
<tr>
<td>11:05AM</td>
<td>Clinical Application of Liquid Biopsies and Genotype-directed Targeted Therapies for Metastatic Breast Cancer</td>
<td>Aditya Bardia, MD, MPH</td>
<td>MGH</td>
</tr>
<tr>
<td>11:50AM</td>
<td>Digital RNA-based Analysis of Circulating Tumor Cells for Noninvasive Monitoring of Cancer</td>
<td>Daniel Haber, MD, PhD</td>
<td>MGH</td>
</tr>
<tr>
<td>12:35PM</td>
<td>Lunch Buffet and Exhibits</td>
<td></td>
<td>5th Floor Rotunda</td>
</tr>
<tr>
<td>1:10PM</td>
<td>2018 Young Investigator Award Presentation</td>
<td></td>
<td>Ballroom</td>
</tr>
</tbody>
</table>

### Session 3: Progress in Immunotherapy
**Moderator:** Joseph R. Bertino, MD, Rutgers Cancer Institute of New Jersey

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:20PM</td>
<td>CAR-T Cell Therapy of Ovarian Cancer</td>
<td>Oladapo Yeku, MD, PhD</td>
<td>MGH</td>
</tr>
<tr>
<td>2:05PM</td>
<td>Molecular Tumor Board: Resistance to Checkpoint Inhibitors</td>
<td>David Liu, MD, MPH, MS</td>
<td>MGH Center for Cancer Research and Ryan Sullivan, MD, MGH</td>
</tr>
<tr>
<td>2:50PM</td>
<td>Break/Exhibits</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Session 4: Junior Faculty Forum
**Moderator:** Bruce A. Chabner, MD, MGH Cancer Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:10PM</td>
<td>The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer</td>
<td>Laura M. Spring, MD</td>
<td>MGH</td>
</tr>
<tr>
<td>3:40PM</td>
<td>Clinical Utility of Longitudinal Molecular Profiling for Management of ALK-Positive Lung Cancer</td>
<td>Ibiayi Dagogo-Jack, MD</td>
<td>MGH</td>
</tr>
<tr>
<td>4:10PM</td>
<td>New Biomarkers in a Novel Antibody-drug Conjugate for Triple Negative Breast Cancer</td>
<td>Aiko Nagayama, MD, PhD</td>
<td>MGH</td>
</tr>
<tr>
<td>4:40PM</td>
<td>Lin28B, a Promoter of Metastasis and Drug Resistance</td>
<td>Joseph Franses, MD, PhD</td>
<td>MGH</td>
</tr>
<tr>
<td>5:25PM</td>
<td>Closing Remarks and Adjourn</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:30PM</td>
<td>Reception: <em>Canaries in a Blue Coal Mine</em> featuring Marine Natural Life Sculptures by Gar Waterman, New Haven</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* *this session not approved for AMA PRA Category 1 Credit™*
Overview
In the field of oncology, the rapid pace of discovery and a better understanding of prevention, detection, the microenvironment, and treatment of cancer will lead to improved patient outcomes. Accurately tailored cancer treatment and individualized therapy will focus on tumor biology and host factors. The healthcare provider will need to be well informed in order to provide the most effective therapy for a particular patient with the fewest associated risks and toxicities. In oncology, our understanding of the complexity of the disease is expanding at an exponential rate.

Target Audience
This activity is designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Society for Translational Oncology and The Massachusetts General Hospital. The Society for Translational Oncology is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Society for Translational Oncology designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Evaluation
STO encourages all participants to complete the meeting evaluation forms following each session. Your feedback will be utilized by the Colloquium leadership committee to develop new initiatives, gauge educational impact, and plan for future meetings.

CME Credit
In order to receive CME credit, learners must sign in, review the CME information (accreditation, learning objectives, faculty disclosures, etc.), attend the CME activity, and complete the meeting evaluation either on paper or online, indicating the number of credit hours claimed. Certificates will be provided upon completion of the evaluation.

ACKNOWLEDGMENTS
STO gratefully acknowledges educational grants in partial support of this activity from:

- Amgen
- Celgene
- EMD Serono, Inc.
- Janssen R&D, LLC
- Novartis Pharmaceuticals Corp.

STO gratefully acknowledges the following exhibitors:

- Amgen
- Novartis Oncology
- Eisai, Inc.
- Takeda

THE PHYSICIAN PAYMENTS SUNSHINE ACT (SUNSHINE ACT) COMPLIANCE
Effective August 1, 2013, The Centers for Medicare & Medicaid Services (CMS) required reporting of any direct or indirect payments made to any US Healthcare Professional by pharmaceutical and device manufacturers and applicable group purchasing organizations (GPOs) under its Open Payments program.

STO will comply with the requirements of those companies who have provided support for this CME activity regarding the appropriate reporting of all direct and indirect payments to healthcare professionals.

In co-providership with: MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER

Brought to you in partnership with: The Oncologist
In accordance with ACCME Standards for Commercial Support and the policies of the Society for Translational Oncology (STO), persons participating in this activity who are in a position to control the content have disclosed all relevant relationships with any commercial interest. On the basis of disclosed information, STO identifies and resolves all conflicts of interest before delivery of content.

STO staff involved in the development of this activity have nothing to disclose.

The following faculty have indicated that they have had relevant financial relationship(s) with a commercial interest within the past 12 months or that they have nothing to disclose.

### CME Faculty Disclosures

**Aditya Bardia**  
*Consultant/advisory role*: Immunomedics, Merck, Novartis, Pfizer, Radius  

**Joseph R. Bertino**  
Nothing to disclose

**Bruce A. Chabner**  
*Consultant/advisory role and honoraria*: PharmaMar, EMD Serono, Cyteir  
*Ownership interest*: Biomarin, Seattle Genetics, PharmaMar, Loxo, Blueprint, Bluebird, Immunomedics  
*Expert testimony*: Eli Lilly, Genentech

**Ibiyi Dagogo-Jack**  
Nothing to disclose

**David E. Fisher**  
*Intellectual property rights*: Soltego  
*Consultant/advisory role*: Soltego  
*Ownership interest*: Soltego

**Joseph Franses**  
*Consultant/advisory role*: Foundation Medicine

**Daniel Haber**  
*Intellectual property rights*: Patent application for CTC-Chip and CTC Signatures  
*Consultant/advisory role*: Janssen SAB  
*Other*: Co-founder, Torpedo Dx (no equity)

**Anthony Letai**  
*Intellectual property rights*: BHS profiling  
*Consultant/advisory role*: Novartis, AbbVie, AstraZeneca  
*Research funding*: Novartis, AbbVie, AstraZeneca  
*Ownership interest*: Flash Therapeutics, Vivid Bioscience

**David Liu**  
Nothing to disclose

**Aiko Nagayama**  
*Ownership interest*: Chugai

**Victoria Richon**  
*Employment*: Ribon Therapeutics  
*Consultant/advisory role*: Hotspot Therapeutics  
*Ownership interest*: Ribon Therapeutics, Hotspot Therapeutics

**David Spriggs**  
Nothing to disclose

**Laura M. Spring**  
Nothing to disclose

**Shannon Stott**  
*Employment (spouse)*: Bioventus  
*Consultant/advisory role*: Mantra Bio, Seventh Sense Bio  
*Ownership interest (spouse)*: Bioventus

**Ryan Sullivan**  
*Consultant/advisory role*: Amgen, Merck, Novartis, Replimmune, Compugen, Syndax  
*Research funding*: Amgen, Merck, Infinity, Sanofi, Lilly, Takeda, Adaptimmune, Asana, Aeglea, Astex, Genentech, Moderna, Viralytics

**Oludapo Yeku**  
Nothing to disclose

It is the responsibility of all faculty to disclose at the start of their presentations whether they will be describing the use of a device, product, or drug that is not FDA approved or is an off-label use of an approved device, product, or drug or is an unapproved usage.

### Learning Objectives

At the conclusion of this meeting, participants will be better able to:

- Describe new cancer-targeting pathways and potential agents for treatment of malignant disease.
- Identify patients who would benefit from targeted cancer therapy, especially those patients who should consider enrollment in clinical trials.
- Distinguish new and emerging biomarkers that may better identify patients with cancer who would benefit most from targeted therapies.